Bosutinib

Drug Profile

Bosutinib

Alternative Names: Bosulif; PF-05208763; PF-5208763; SKI-606

Latest Information Update: 07 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Wyeth
  • Developer Avillion; Massachusetts General Hospital; Pfizer; University of Texas M. D. Anderson Cancer Center
  • Class Aniline compounds; Antineoplastics; Nitriles; Piperazines; Quinolines; Small molecules
  • Mechanism of Action Bcr-abl tyrosine kinase inhibitors; Src-Family kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Chronic myeloid leukaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Chronic myeloid leukaemia
  • Phase II Glioblastoma
  • Phase I/II Acute lymphoblastic leukaemia
  • Discontinued Autosomal dominant polycystic kidney disease; Breast cancer; Solid tumours

Most Recent Events

  • 29 Aug 2017 Bosutinib receives priority review status for Chronic myeloid leukaemia (First-line therapy, Newly diagnosed) in USA
  • 29 Aug 2017 EMA validated for review a Type II Variation application for bosutinib for Chronic myeloid leukaemia (First-line therapy, Newly diagnosed)
  • 29 Aug 2017 The US FDA accepts sNDA for bosutinib for Chronic myeloid leukaemia (First-line therapy, Newly diagnosed) for review
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top